These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

132 related items for PubMed ID: 788750

  • 1. The pharmacodynamics of single doses of prorenoate potasssium and spironolactone in fludrocortisone treated normal subjects.
    Ramsay LE, Shelton JR, Tidd MJ.
    Br J Clin Pharmacol; 1976 Jun; 3(3):475-82. PubMed ID: 788750
    [Abstract] [Full Text] [Related]

  • 2. Relative potency of prorenoate and spironolactone in normal man.
    Ramsay L, Harrison I, Shelton J, Tidd M.
    Clin Pharmacol Ther; 1975 Oct; 18(4):391-400. PubMed ID: 1100306
    [Abstract] [Full Text] [Related]

  • 3. Antagonism of endogenous mineralocorticoids in normal subjects by prorenoate potassium and spironolactone.
    Levine D, Ramsay L, Auty R, Branch R, Tidd M.
    Eur J Clin Pharmacol; 1976 Mar 22; 09(5-6):381-6. PubMed ID: 786663
    [Abstract] [Full Text] [Related]

  • 4. Spironolactone and canrenoate-K: relative potency at steady state.
    Ramsay L, Asbury M, Shelton J, Harrison I.
    Clin Pharmacol Ther; 1977 May 22; 21(5):602-9. PubMed ID: 858213
    [Abstract] [Full Text] [Related]

  • 5. Spironolactone and potassium canrenoate in normal man.
    Ramsay L, Shelton J, Harrison I, Tidd M, Asbury M.
    Clin Pharmacol Ther; 1976 Aug 22; 20(2):167-77. PubMed ID: 780038
    [Abstract] [Full Text] [Related]

  • 6. Prolactin, diuretics and urinary electrolytes in normal subjects.
    Auty R, Branch RA, Cole EN, Levine D, Ramsay L.
    J Endocrinol; 1976 Aug 22; 70(2):173-81. PubMed ID: 965879
    [Abstract] [Full Text] [Related]

  • 7. Paradoxical potassium excretion in response to aldosterone antagonists.
    Ramsay LE, Harrison IR, Shelton JR, Tidd MJ.
    Eur J Clin Pharmacol; 1977 Jan 03; 11(2):101-5. PubMed ID: 837961
    [Abstract] [Full Text] [Related]

  • 8. Steady-state relative potency of aldosterone antagonists: spironolactone and prorenoate.
    McInnes GT, Shelton JR, Harrison IR.
    Clin Pharmacol Ther; 1981 May 03; 29(5):679-86. PubMed ID: 7214797
    [Abstract] [Full Text] [Related]

  • 9. Bioassay of aldosterone antagonists in normal human subjects: a relationship between the level of plasma uric acid before treatment and apparent drug responses.
    Ramsay LE, Hessian P, Tidd MJ.
    Br J Clin Pharmacol; 1975 Jun 03; 2(3):271-6. PubMed ID: 1234508
    [Abstract] [Full Text] [Related]

  • 10. Potassium prorenoate: a new steroidal aldosterone antagonist.
    Hofmann LM, Chinn LJ, Pedrera HA, Krupnick MI, Suleymanov OD.
    J Pharmacol Exp Ther; 1975 Aug 03; 194(2):450-6. PubMed ID: 1151770
    [Abstract] [Full Text] [Related]

  • 11. Comparison of prorenoate potassium and spironolactone after repeated doses and steady state plasma levels of active metabolites.
    McInnes GT, Shelton JR, Harrison IR, Perkins RM, Palmer RF.
    Br J Clin Pharmacol; 1982 Feb 03; 13(2):187-94. PubMed ID: 7059416
    [Abstract] [Full Text] [Related]

  • 12. Dose-response relationships for spironolactone at steady state.
    McInnes GT, Perkins RM, Shelton JR, Harrison IR.
    Clin Pharmacol Ther; 1982 Mar 03; 31(3):317-23. PubMed ID: 7060315
    [Abstract] [Full Text] [Related]

  • 13. Spironolactone dose-response relationships in healthy subjects.
    McInnes GT, Perkins RM, Shelton JR, Harrison IR.
    Br J Clin Pharmacol; 1982 Apr 03; 13(4):513-8. PubMed ID: 7066166
    [Abstract] [Full Text] [Related]

  • 14. Effect of mineralocorticoid activity on transtubular potassium gradient, urinary [K]/[Na] ratio, and fractional excretion of potassium.
    Chacko M, Fordtran JS, Emmett M.
    Am J Kidney Dis; 1998 Jul 03; 32(1):47-51. PubMed ID: 9669423
    [Abstract] [Full Text] [Related]

  • 15. Antagonism of aldosterone in normal subjects by Ro 12-2503 and spironolactone.
    Dux S, Rosenfeld J, Cocco G, Chu D, Gasser DF.
    Arzneimittelforschung; 1982 Jul 03; 32(2):164-9. PubMed ID: 7199923
    [Abstract] [Full Text] [Related]

  • 16. Comparative effects of canrenoate-K and prorenoate-K upon aldosterone biosynthesis in perifused frog interrenal glands.
    Delarue C, Leboulenger F, Tonon MC, Jegou S, Leroux P, Kusmierek MC, Corvol P, Vaillant R, Vaudry H.
    Steroids; 1979 Sep 03; 34(3):319-32. PubMed ID: 494369
    [Abstract] [Full Text] [Related]

  • 17. Acute effect of potassium canrenoate administration on renin-angiotensin, kallikrein-kinin and prostaglandin systems.
    Lahera V, Cachofeiro V, Duran F, Cañizo FJ, Rodriguez FJ, Tresguerres JA.
    Gen Pharmacol; 1988 Sep 03; 19(6):835-9. PubMed ID: 3068096
    [Abstract] [Full Text] [Related]

  • 18. Improved method for comparative evaluation of aldosterone antagonists in healthy man.
    Casals-Stenzel J, Schmalbach J, Losert W.
    Eur J Clin Pharmacol; 1977 Dec 02; 12(4):247-55. PubMed ID: 590311
    [Abstract] [Full Text] [Related]

  • 19. Dose-response relationships for spironolactone in combination with a potassium-wasting diuretic.
    McInnes GT, Clarke JM, Shelton JR.
    Clin Pharmacol Ther; 1983 Jan 02; 33(1):35-43. PubMed ID: 6848297
    [Abstract] [Full Text] [Related]

  • 20. Re-evaluation of the antimineralocorticoid effect of the spironolactone metabolite, canrenone, from plasma concentrations determined by a new high-pressure liquid-chromatographic method.
    Dahlöf CG, Lundborg P, Persson BA, Regårdh CG.
    Drug Metab Dispos; 1979 Jan 02; 7(2):103-7. PubMed ID: 38071
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.